Alembic Pharma Q1 FY27: Revenue up 26% YoY to Rs 2,150 Cr

Revenue Growth 20pctResults View source PDF Explain this filing

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.7%Reaction day

₹805.05

prior close

₹809.90

announcement price

In-mkt

timing

Nifty Microcap 250market+0.4%+0.3% vs market

Pharmaceuticals peers, median of 165sector-0.0%+0.8% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.1

15m

-0.1

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.7+0.4+0.3-0.0+0.8

Next day

+1.4+1.7-0.4+0.0+1.4

+3.7+2.1+1.6+0.2+3.6

+3.6+2.1+1.4+0.4+3.2

+3.6+2.1+1.5+0.6+3.0

+4.3+1.9+2.4+0.8+3.5

+3.2+2.4+0.8+0.4+2.8

15d

-0.0+3.0-3.0+0.5-0.5

+0.1+3.7-3.7+1.1-1.1

+3.3+1.6+1.8+2.0+1.4

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alembic Pharma reported Q1 FY27 consolidated results with revenue up 26% YoY to Rs 2,150 Cr. PAT rose 12% YoY to Rs 173 Cr. EBITDA pre R&D stood at Rs 523 Cr with 24% margin. US formulations surged 49% to Rs 778 Cr, API grew 33% to Rs 346 Cr, Ex-US generics up 17% to Rs 383 Cr, and India branded up 7% to Rs 642 Cr. Filing is a revised press release of unaudited results.

Likely market impact

Broad-based growth led by strong US performance signals positive momentum for the stock and shareholders.